Advertisement
PTC Therapeutics Granted Marketing Authorization By EU For Upstaza To Treat AADC Deficiency
(RTTNews) - PTC Therapeutics, Inc. (PTCT) announced Wednesday that Upstaza (eladocagene exuparvovec) was granted marketing authorization by the European Commission. Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and the first marketed gene therapy directly infused into the brain. It is approved for patients 18 months and older.
Upstaza is a one-time gene replacement therapy indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of AADC deficiency with a severe phenotype.
The marketing authorization is applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.
For More Such Health News, visit rttnews.com
read more
FDA Approves PTC's Kebilidi As First Gene Therapy To Treat AADC Deficiency
The U.S. Food and Drug Administration approved PTC Therapeutics, Inc.'s Kebilidi (eladocagene exuparvovec-tneq) gene therapy for the treatment of aromatic L-amino acid decarboxylase or AADC deficiency. Kebilidi is the first FDA-approved gene therapy for the deficiency. PTC shares gained around 8.5 percent in the extended trading on the Nasdaq on Thursday.
RTTNews
|
180 дней спустя
PTC Therapeutics Says European Commission Returns Translarna Opinion To CHMP For Re-evaluation
PTC Therapeutics, Inc. (PTCT) announced Monday that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna (ataluren) and has returned the opinion to the CHMP for re-evaluation.
RTTNews
|
358 дней спустя
Sensex, Nifty Open Higher On Rate Cut Hopes
Indian shares were notably higher on Wednesday as signs of easing retail inflation sparked hopes for more rate cuts from the Reserve Bank of India in coming months.
RTTNews
|
4 минут назад
Australian Market Maintains Slight Losses In Mid-market
The Australian stock market is maintaining its slight losses in mid-market moves on Wednesday, snapping a five-session winning streak, with the benchmark S&P/ASX 200 staying well below the 8,300 level, following the mixed cues from Wall Street overnight, with a mixed performance across most sectors. Traders are also booking some profits following the recent upside in the markets.
RTTNews
|
58 минут назад
Asian Markets Trade Mixed
Asian stock markets are trading mixed on Wednesday, following the mixed cues from Wall Street overnight, as traders assess the impact a temporary US-China tariff war settlement, under which tariffs will be reduced to 30 percent and 10 percent, respectively, for a 90-day period. They also cautiously await trade deals with other major US trading partners. Asian markets closed mixed on Tuesday.
RTTNews
|
1ч 42мин назад
Sensex, Nifty Seen Higher At Open
Indian shares look set to open on a positive note Wednesday after official data showed India's consumer price inflation eased further in April to the lowest level in nearly six years amid a slower rise in food prices.
RTTNews
|
2ч 1мин назад
Thai Bourse Likely To Remain Rangebound
The Thai stock market has alternated between positive and negative finishes through the previous five trading days since the end of the five-day winning streak in which it had advanced more than 50 points or 4.3 percent. The Stock Exchange of Thailand now sits just beneath the 1,215-point plateau and it's poised to inch higher again on Wednesday.
RTTNews
|
2ч 33мин назад
Japanese Market Notably Lower
The Japanese stock market is trading notably lower on Wednesday after opening in the green, snapping a four-session winning streak, following the mixed cues from Wall Street overnight. The Nikkei 225 is falling to near the 37,900 level, with weakness in exporters and automaker stocks partially offset by gains in technology and financial stocks.
RTTNews
|
3ч 1мин назад
